Spike Recovery in Immunoassays

By Dr. Zubair Khalid, DVM, MS, PhD · 2026-08-21

Quick Answer

• Spike recovery experiments measure how accurately an immunoassay detects a known amount of analyte added to a biological sample, revealing matrix effects that can distort results.
• Design recovery tests with at least three spike levels spanning the assay's working range, calculate percent recovery as (measured spike minus endogenous) divided by expected spike, and set acceptance criteria before running samples.
• Recovery outside the accepted range does not automatically invalidate an assay, but it requires investigation of interfering substances and may demand changes to sample preparation or assay format.

At a Glance

Spike recovery is a core analytical validation step for immunoassays used in research and clinical laboratories. The procedure involves adding a known quantity of purified analyte to a biological sample, measuring the total analyte concentration, and comparing the measured increase to the amount added. Recovery percentages near 100 percent indicate that the sample matrix does not interfere with detection, while values substantially above or below 100 percent signal the presence of matrix components that enhance or suppress the signal.

Understanding Matrix Effects in Immunoassays

Immunoassays quantify analytes in complex biological fluids that contain proteins, lipids, salts, metabolites, and other components. These constituents form the sample matrix, and they can interfere with the antibody-antigen interaction, enzyme activity, or detection signal in ways that produce inaccurate measurements. The clinical importance of this problem is well established, since physicians rely on immunoassay results to guide patient care and interfering substances can compromise the accuracy and precision of those tests. Researchers developing assays for extracellular vesicle surface proteins, cytokines, and neurodegenerative disease biomarkers routinely include spike recovery experiments in their validation workflows to document that their methods perform reliably in the intended sample types.

Matrix effects arise through several mechanisms. Endogenous antibodies in the sample can bind to the assay antibodies or to the analyte itself, blocking detection. Heterophilic antibodies, rheumatoid factors, and human anti-mouse antibodies are common culprits in clinical samples. High concentrations of unrelated proteins can cause nonspecific binding to the plate or beads, increasing background signal. Components such as bilirubin, hemoglobin, lipids, and biotin can interfere with enzyme-based detection systems. The physical properties of the matrix, including pH, ionic strength, and viscosity, can also alter binding kinetics. Because these factors vary between individuals and between sample types, an assay validated in one matrix cannot be assumed to perform identically in another.

The practical consequence of matrix effects is that a sample containing a true analyte concentration of 50 units might read as 40 or 65 units depending on the direction and magnitude of interference. Spike recovery provides a direct measurement of this distortion. When a known amount of purified analyte is added to the sample, the assay should detect the sum of the endogenous analyte plus the spike. If the measured total falls short of the expected value, the matrix is suppressing detection. If it exceeds the expected value, the matrix is enhancing the signal or contributing nonspecific reactivity.

Matrix effects are not always constant across the assay's working range. A matrix component that interferes at low analyte concentrations may be negligible at high concentrations, or vice versa. This is why spike recovery experiments must include multiple spike levels instead of a single concentration. Testing only one level can miss a concentration-dependent interference that would compromise measurements in part of the calibration range.

The nature of the analyte itself also shapes matrix effect profiles. For example, TDP-43 in plasma is largely compartmentalized within platelets instead of freely circulating, and variable platelet recovery during blood processing can create substantial heterogeneity in measured levels across archived samples. This observation demonstrates that pre-analytical variables, including how blood is collected, processed, and stored, can produce matrix-related artifacts that spike recovery experiments may not fully capture if the spike material behaves differently from the endogenous analyte. Similarly, extracellular vesicle surface proteins present a distinct challenge because the analyte is anchored to membranous particles, and the vesicle's physical state, size, and surface composition can influence antibody accessibility and detection efficiency in ways that soluble recombinant spike proteins cannot replicate.

Core Principles of Spike Recovery Design

Selecting the Analyte and Spike Material

The spike material should be the same analyte that the assay is designed to measure, or a well-characterized preparation that behaves identically in the assay. Purified recombinant proteins are commonly used for cytokine assays, while purified native proteins or reference standards may be appropriate for other analytes. The spike material must be free of contaminants that could interfere with the assay or contribute to the measured signal through cross-reactivity.

The choice of spike material affects the interpretation of recovery results. A recombinant protein may not fold identically to the native analyte in the sample, and antibodies that recognize conformational epitopes may bind the two forms differently. This discrepancy can produce recovery values that reflect differences between the recombinant and native proteins instead of true matrix effects. When possible, the spike material should be matched to the calibration standard used in the assay, since the calibration curve establishes the relationship between signal and concentration.

For analytes that exist in multiple isoforms or binding states, the spike material should represent the form that the assay is intended to measure. Brain-derived tau, for instance, requires an assay that distinguishes the central-nervous-system-enriched tau441 isoform from the peripherally enriched big-tau isoform. A spike recovery experiment using the wrong isoform would produce misleading results, since the assay's specificity for one isoform would not be tested by spiking with the other. The development of the BD-tau Advantage PLUS assay demonstrated that signals were highly specific to tau441 but not to big-tau, and this specificity was a prerequisite for meaningful spike recovery testing.

Choosing Spike Concentrations

Spike levels should span the assay's dynamic range to detect concentration-dependent matrix effects. A common approach is to spike at a low concentration near the limit of quantitation, a mid-range concentration, and a high concentration approaching the upper limit of the calibration curve. The endogenous analyte concentration in the sample determines the total concentration after spiking, so samples with high endogenous levels may require larger spikes to produce measurable increases.

The spike volume should be small relative to the sample volume to minimize dilution of the matrix. Adding a large volume of buffer or diluent changes the matrix composition and can reduce or eliminate the very interferences the experiment is designed to detect. A spike volume of 10 percent or less of the total sample volume is a practical guideline, though the exact proportion depends on the assay format and the concentration of the spike stock solution.

When the endogenous analyte concentration is high, the measured increase from the spike becomes a small fraction of the total signal, making the recovery calculation sensitive to small errors in the endogenous measurement. In such cases, selecting samples with low endogenous analyte levels, or using a surrogate matrix that lacks the analyte entirely, can improve the sensitivity of the recovery measurement. Alternatively, the spike concentration can be increased to ensure that the added analyte represents a substantial fraction of the total measured signal.

Preparing the Spike Stock Solution

The spike stock solution must be prepared accurately, since the expected recovery calculation depends on knowing the exact amount of analyte added. Serial dilutions from a concentrated stock introduce cumulative errors, so each dilution step should be performed carefully with proper mixing. The stock solution should be prepared fresh or stored under conditions that maintain analyte stability, following the manufacturer's recommendations or established laboratory protocols.

The diluent used to prepare the spike stock should be compatible with the sample matrix. Phosphate-buffered saline or the assay's sample diluent are common choices. The spike stock should not contain high concentrations of carrier proteins or detergents that could alter the matrix composition when added to the sample.

Calibrator traceability is an important consideration when preparing spike stocks. The development of an automated IL-6 immunoassay compared calibrator and panel preparations using an internal recombinant IL-6 standard against serum panels prepared with the IL-6 International Standard 89/548. This comparison ensured that the spike material and the calibration standard were aligned, so that recovery values reflected matrix effects instead of discrepancies between different standard preparations. When an international reference standard exists for the analyte of interest, using it or a preparation traceable to it strengthens the validity of spike recovery results.

Matrix Selection and Sample Handling

Each sample type that will be tested in the assay should be evaluated for matrix effects. Serum and plasma are common clinical matrices, but they differ in composition. Plasma contains fibrinogen and anticoagulants, while serum is produced after blood clotting removes these components. Urine, cerebrospinal fluid, saliva, and cell culture supernatants each present distinct interference profiles. An assay validated in serum may not perform acceptably in plasma or urine.

The choice between serum and plasma can itself be a source of matrix-related variability. An evaluation of a commercial brain-derived tau assay examined matrix effects by comparing BD-tau levels in 48 plasma and serum sample pairs and 20 plasma and cerebrospinal fluid sample pairs. Significant correlations were observed in both comparisons, but the correlation between plasma and serum (r = 0.8392) differed from the correlation between plasma and cerebrospinal fluid (r = 0.6150), indicating that the matrix composition influenced measured levels. This type of comparison should be part of assay validation when multiple sample types will be used.

Samples used for spike recovery experiments should be representative of the intended test population. Pooled samples from multiple donors can provide an average matrix composition, but individual samples may contain unique interfering substances. Testing a small panel of individual samples can reveal variability in matrix effects across the population. Samples should be collected, processed, and stored according to standard protocols, since hemolysis, lipemia, and repeated freeze-thaw cycles can introduce or amplify interferences.

The stability of the analyte under storage conditions is another factor that affects spike recovery interpretation. The evaluation of the BD-tau assay demonstrated that signals were stable for up to four freeze-thaw cycles, which supported the reliability of measurements in samples that undergo repeated handling. If an analyte is unstable to freeze-thaw cycles, spike recovery results from stored samples may reflect degradation instead of matrix effects, and the experiment should be designed to account for this possibility.

Calculating Spike Recovery

The Recovery Formula

Spike recovery is calculated by comparing the measured analyte concentration in the spiked sample to the expected concentration. The expected concentration is the sum of the endogenous analyte concentration in the unspiked sample and the concentration of the added spike. The formula is:

Percent recovery = (measured concentration in spiked sample minus endogenous concentration in unspiked sample) divided by (spike concentration) multiplied by 100

The endogenous concentration must be measured in the same assay run as the spiked samples, since run-to-run variation in calibration can affect the calculation. The spike concentration is the nominal concentration calculated from the volume and concentration of the spike stock solution added to the sample.

Accounting for Dilution

If the spiked sample is diluted before measurement, the dilution factor must be applied to both the measured concentration and the expected concentration. The measured concentration from the diluted sample is multiplied by the dilution factor to obtain the concentration in the undiluted spiked sample. The expected concentration is calculated using the endogenous concentration in the undiluted unspiked sample plus the spike concentration in the undiluted spiked sample.

Dilution can also be used as a diagnostic tool when recovery is poor. If a sample shows low recovery at high spike levels, diluting the sample before spiking may reduce the concentration of interfering substances. Serial dilution of a spiked sample should produce a linear decrease in measured concentration if the matrix effect is constant. Nonlinear dilution curves indicate that the matrix effect is concentration-dependent.

Dilution linearity is closely related to spike recovery and is often evaluated in the same validation study. The BD-tau assay evaluation demonstrated that concentrations decreased linearly up to 16-fold dilution, and the TDP-43 immunoassay qualification included both spike recovery and dilution linearity as separate parameters. These two experiments provide complementary information: spike recovery tests the accuracy of detecting a known addition, while dilution linearity tests whether the measured concentration scales proportionally when the sample is diluted. Both are necessary to characterize matrix effects fully.

Interpreting Recovery Values

Recovery values near 100 percent indicate that the matrix does not substantially interfere with detection. Values between 80 and 120 percent are commonly considered acceptable for research assays, though the appropriate range depends on the assay's intended use and the regulatory or publication standards that apply. Clinical assays may require tighter acceptance criteria, while exploratory research assays may tolerate wider ranges.

Published validation studies provide examples of recovery ranges that were considered acceptable for specific assays. The automated IL-6 immunoassay demonstrated spike recovery of 90 to 110 percent in serum and plasma, and the BD-tau assay demonstrated spike recovery of 86 to 96 percent. These ranges reflect the performance characteristics of each assay and the requirements of their intended applications. The acceptance criteria for a new assay should be informed by such precedents but must be established based on the specific assay's performance and intended use.

Recovery consistently below 100 percent suggests signal suppression. Possible causes include endogenous antibodies blocking the analyte, proteases degrading the spike, or matrix components inhibiting the detection enzyme. Recovery consistently above 100 percent suggests signal enhancement, which can result from nonspecific binding, cross-reactivity with matrix components, or the presence of endogenous analyte that cross-reacts with the detection antibodies.

The pattern of recovery across spike levels provides additional diagnostic information. If recovery is low at all spike levels, the interference may be saturable, meaning the matrix contains a limited amount of an interfering substance. If recovery decreases with increasing spike concentration, the interference may be competitive, with the matrix component competing with the analyte for antibody binding. If recovery increases with spike concentration, the interference may be nonspecific, with the matrix contributing a constant background signal that becomes proportionally smaller at higher analyte concentrations.

Practical Workflow for Spike Recovery Experiments

Step 1: Define the Assay and Acceptance Criteria

Before beginning the experiment, document the assay protocol, the calibration range, and the acceptance criteria for recovery. The acceptance criteria should be based on the assay's intended use and any applicable guidelines. For research assays, a recovery range of 80 to 120 percent is a common starting point, but the criteria should be justified by the assay's performance requirements.

The assay protocol should specify the sample type, the sample preparation steps, the antibody pair, the detection system, and the calibration procedure. Any deviation from the standard protocol during spike recovery testing should be documented, since the results are intended to validate the assay as it will be performed for actual samples.

Step 2: Prepare Samples and Spike Solutions

Select representative samples for each matrix type to be tested. Prepare the spike stock solution at a concentration that allows the desired spike levels to be added in a small volume. Calculate the volume of spike solution needed for each spike level based on the sample volume and the target spike concentration.

The number of samples and spike levels should be determined by the validation plan. A minimal design includes one pooled sample per matrix type with three spike levels, each tested in duplicate. A more thorough design includes multiple individual samples to assess inter-individual variability. The available sample volume and assay capacity will constrain the design.

Step 3: Spike and Measure

Aliquot the sample into tubes for each spike level plus an unspiked control. Add the spike solution to the appropriate tubes and mix thoroughly. Include a buffer control spiked with the same concentrations to verify that the spike solution itself is measured accurately in the absence of matrix. Run all samples in the same assay plate or run to minimize between-run variation.

The order of sample loading on the plate should be randomized or arranged to minimize positional effects. Edge effects, where wells at the plate periphery read differently from central wells, can introduce systematic variation that confounds recovery calculations. Including the unspiked control and all spike levels for a given sample on the same plate reduces the impact of between-plate variation.

Step 4: Calculate Recovery

Measure the analyte concentration in each sample. Subtract the endogenous concentration in the unspiked sample from the concentration in each spiked sample. Divide by the nominal spike concentration and multiply by 100 to obtain percent recovery. Record the results for each spike level and each sample.

The calculation should be performed using the raw measured concentrations before any rounding or transformation. If the assay software applies a curve-fitting algorithm, the calculated concentrations should be exported with sufficient decimal places to avoid rounding errors in the recovery calculation.

Step 5: Evaluate and Document

Compare the recovery values to the acceptance criteria. If recovery is within the accepted range for all spike levels and sample types, document the results and proceed with assay validation. If recovery falls outside the accepted range, investigate the cause and consider modifications to the assay protocol or sample preparation.

The documentation should include the experimental design, the acceptance criteria, the results for each spike level and sample type, and any troubleshooting steps taken. This record supports the assay validation file and provides a basis for comparison if the assay is modified or transferred to another laboratory.

Options and Tradeoffs in Spike Recovery Design

Single versus Multiple Spike Levels

A single spike level provides a quick check for gross matrix effects but cannot detect concentration-dependent interference. Multiple spike levels provide more information but require more sample volume, more reagents, and more assay plates. The number of spike levels should balance the need for thorough validation against practical constraints. Three levels spanning the dynamic range is a reasonable compromise for most applications.

The choice of spike levels should be guided by the assay's calibration range and the expected analyte concentrations in the test samples. If the assay will be used to measure samples with a narrow range of analyte concentrations, spike levels concentrated in that range may be more informative than levels spread across the full dynamic range. Conversely, if the assay will be used for samples with widely varying analyte concentrations, spike levels spanning the full range are appropriate.

Pooled versus Individual Samples

Pooled samples provide an average matrix composition and reduce the number of assays needed. Individual samples reveal variability in matrix effects across the population but require more assays and more careful interpretation. A common approach is to test pooled samples for initial validation and then test a small panel of individual samples to assess variability.

The number of individual samples needed to characterize variability depends on the expected heterogeneity of the test population. For clinical samples, factors such as age, sex, medication use, and disease state can influence matrix composition. The evaluation of the LuminEV assay for extracellular vesicle surface proteins measured tetraspanin levels in blood plasma from 70 disease-free donors and found that CD63 displayed a weak but significant negative correlation with age and was slightly lower in female samples. This type of population-level variability should be considered when designing spike recovery experiments for assays intended to measure analytes in diverse patient populations.

Buffer Controls

Including buffer controls spiked with the same concentrations as the samples helps distinguish matrix effects from errors in spike preparation. If recovery is poor in both buffer and samples, the problem likely lies in the spike solution or the assay itself. If recovery is acceptable in buffer but poor in samples, the matrix is the source of interference.

Buffer controls also serve as a check on the accuracy of the spike stock preparation. If the buffer control recovery is consistently above or below 100 percent, the nominal spike concentration may be incorrect, and the stock solution should be re-prepared or re-quantified.

Endogenous Analyte Considerations

Samples with high endogenous analyte concentrations present a challenge for spike recovery experiments. The measured increase from the spike becomes a small fraction of the total signal, making the recovery calculation sensitive to small errors in the endogenous measurement. Using samples with low endogenous analyte levels, or using a matrix that lacks the analyte entirely, can improve the sensitivity of the recovery measurement.

For analytes that are present at very low levels in most samples, such as cytokines in healthy individuals, the endogenous concentration may be below the limit of quantitation. In this case, the endogenous concentration can be treated as zero for the recovery calculation, but this assumption should be documented and its impact on the interpretation of results should be considered.

Records and Measurements

Essential Data to Record

Documenting spike recovery experiments thoroughly supports troubleshooting, assay transfer, and publication. The following information should be recorded for each experiment:

Quality Controls

Each assay run should include the standard curve, quality control samples at known concentrations, and the unspiked sample. Quality control results should be within the manufacturer's or laboratory's accepted ranges before spiked sample results are interpreted. If quality controls fail, the run should be repeated instead of attempting to interpret spiked sample results from an invalid run.

The standard curve should be evaluated for goodness of fit and the back-calculated concentrations of the calibration standards should be within accepted limits. The limit of detection and limit of quantitation should be established for each run, since these parameters affect the interpretation of recovery at low spike levels.

Reproducibility Assessment

Spike recovery should be assessed in multiple runs to document reproducibility. Running the same spike levels in two or three independent assays provides information about run-to-run variation in recovery. This is particularly important if the assay will be used for longitudinal studies or multi-site collaborations, where consistent performance across runs and operators is essential.

The LuminEV assay validation included inter- and intra-assay precision and reproducibility between operators as part of the overall validation package. Similarly, the BD-tau assay evaluation reported intra- and inter-plate coefficients of variation of 7.24 percent or less for twenty repeated measurements of three plasma samples. These examples illustrate the types of reproducibility data that should accompany spike recovery results in a complete validation.

Common Failure Patterns and Troubleshooting

Low Recovery Across All Spike Levels

Consistently low recovery suggests that the matrix is suppressing the signal or degrading the spike. Possible causes include proteases in the sample that degrade the analyte, endogenous antibodies that sequester the analyte, or matrix components that inhibit the detection enzyme. Adding protease inhibitors to the sample, using a different antibody pair, or diluting the sample before spiking may improve recovery.

The timing of spike addition relative to sample collection and processing can also affect recovery. If the spike is added to a sample that has been stored for an extended period, the matrix composition may have changed, and the recovery results may not reflect the assay's performance with fresh samples. Spike recovery experiments should be performed with samples that have been handled according to the same protocols as the intended test samples.

High Recovery Across All Spike Levels

Consistently high recovery suggests signal enhancement or nonspecific reactivity. Possible causes include heterophilic antibodies that bridge the capture and detection antibodies, cross-reactivity with matrix components, or insufficient washing steps. Using blocking reagents, changing the antibody pair, or increasing the number of wash steps may reduce the enhancement.

The specificity of the assay for the intended analyte should be verified when high recovery is observed. The IL-6 immunoassay development included testing for cross-reactivity to related cytokines and interleukins, and the assay exhibited no cross-reactivity to these related molecules. If an assay lacks specificity, spike recovery results may be inflated by the detection of cross-reactive substances in the matrix.

Recovery Varies by Spike Level

Concentration-dependent recovery indicates that the matrix effect is not constant across the assay's dynamic range. This pattern requires careful interpretation, since the assay may be reliable in one part of the calibration range but not another. The assay's reportable range may need to be restricted to concentrations where recovery is acceptable.

The shape of the recovery curve across spike levels can provide clues about the underlying mechanism. A recovery that decreases with increasing spike concentration may indicate a saturable interference, while a recovery that increases with spike concentration may indicate a constant background signal that becomes proportionally smaller at higher analyte concentrations. These patterns should be documented and considered when setting the assay's reportable range.

Recovery Varies Between Samples

Sample-to-sample variation in recovery indicates that individual samples contain different levels or types of interfering substances. This is common in clinical samples, where patient characteristics such as medication use, disease state, and genetic background influence matrix composition. Testing a panel of individual samples during validation can identify the extent of this variability.

The TDP-43 plasma biomarker study provides a cautionary example of sample-to-sample variability. Biobank-archived plasma samples yielded considerable heterogeneity in TDP-43 levels, and subsequent investigation attributed these differences to variable platelet recovery during sample processing. This finding underscores the importance of understanding pre-analytical variables and their impact on matrix composition when interpreting spike recovery results.

Recovery Is Acceptable in Buffer but Poor in Samples

This pattern confirms that the sample matrix is the source of interference. The buffer control demonstrates that the spike solution and assay reagents are functioning correctly. Troubleshooting should focus on the matrix, including sample preparation, dilution, and blocking strategies.

Sample preparation modifications that may reduce matrix interference include dilution, extraction, precipitation, or filtration to remove interfering components. The choice of modification depends on the nature of the interference and the assay format. Any modification to sample preparation must be re-validated, including repeat spike recovery experiments with the modified protocol.

Welfare and Safety Context

Biosafety Considerations

Spike recovery experiments involve handling biological samples that may contain infectious agents. Human blood products, tissue samples, and cell culture materials require appropriate biosafety precautions. The Biosafety in Microbiological and Biomedical Laboratories guidelines from the CDC and NIH provide a framework for risk assessment and containment practices. Laboratory personnel should follow institutional biosafety protocols, use appropriate personal protective equipment, and perform procedures involving potentially infectious materials in a biosafety cabinet when aerosol generation is possible.

The risk assessment should consider the source of the samples, the potential presence of bloodborne pathogens, and the procedures being performed. Standard precautions should be applied to all human blood and body fluid samples, regardless of the perceived risk. Institutional biosafety committees can provide guidance on the appropriate containment level for specific sample types and procedures.

Recombinant Materials

Spike materials may include recombinant proteins produced from cloned genes. Research involving recombinant or synthetic nucleic acid molecules is subject to the NIH Guidelines for Research Involving Recombinant or Synthetic Nucleic Acid Molecules. Investigators should confirm that their work complies with institutional biosafety committee requirements and that recombinant materials are handled according to the appropriate containment level.

The NIH guidelines apply to research that involves the construction and handling of recombinant nucleic acid molecules and the use of organisms or viruses containing such molecules. Even when the final spike material is a purified protein, the production process may have involved recombinant DNA techniques that fall under the guidelines. Investigators should review their protocols and consult with their institutional biosafety committee to ensure compliance.

Chemical Safety

Assay reagents may include toxic or hazardous chemicals, including enzyme substrates, stop solutions, and preservatives. Material safety data sheets should be reviewed before use, and chemicals should be handled according to institutional safety policies. Waste disposal should follow institutional and regulatory requirements.

The National Institute of Standards and Technology maintains laboratory programs that emphasize measurement science, standards, calibration, and quality. These programs provide a framework for ensuring that laboratory measurements are reliable and that quality practices are integrated into laboratory workflows. Adopting such practices supports the validity of spike recovery experiments and other validation procedures.

Limitations of Spike Recovery

Spike Recovery Does Not Detect All Matrix Effects

Spike recovery measures the assay's ability to detect an added analyte, but it does not directly measure the accuracy of endogenous analyte measurements. A matrix component that interferes with the endogenous analyte but not with the added spike would not be detected by a spike recovery experiment. This limitation is inherent to the method, since the spike is added after the sample is collected and processed, and it may not experience the same conditions as the endogenous analyte.

The TDP-43 platelet study illustrates this limitation. The immunoassays were qualified for spike recovery and dilution linearity in human plasma samples, yet the subsequent discovery that TDP-43 was compartmentalized within platelets and that variable platelet recovery affected measured levels was not predicted by the spike recovery results. The spike material, which was likely a soluble recombinant protein, did not replicate the behavior of the endogenous platelet-associated analyte.

Recombinant Spikes May Not Mimic Native Analyte

The behavior of a recombinant spike protein in the assay may differ from the native analyte in the sample. Differences in post-translational modifications, folding, or binding partners can affect antibody recognition and detection. Recovery values that are acceptable for a recombinant spike do not guarantee that the assay accurately measures the native analyte.

For extracellular vesicle surface proteins, the spike material would need to be presented in a membrane context to mimic the native analyte. A soluble recombinant tetraspanin would not replicate the surface presentation of the endogenous protein on vesicles, and spike recovery results using such a spike would have limited relevance to the assay's performance with actual vesicle samples. The LuminEV assay validation included spike-in recovery as one component, but the interpretation of those results must account for the differences between the spike material and the native vesicle-associated analyte.

Recovery Criteria Are Context Dependent

The acceptable range for spike recovery depends on the assay's intended use. A research assay used for exploratory studies may tolerate wider recovery ranges than a clinical assay used for patient management. Regulatory requirements, publication standards, and laboratory quality policies all influence the appropriate acceptance criteria. Researchers should establish criteria that are appropriate for their specific context and document the rationale.

The MIQE guidelines for quantitative PCR emphasize the importance of comprehensive reporting and transparency in assay validation. While these guidelines were developed for qPCR, the principles of transparent reporting and complete documentation apply equally to immunoassay validation. Spike recovery results should be reported with sufficient detail to allow other laboratories to assess the assay's suitability for their applications.

Spike Recovery Complements Other Validation Parameters

Spike recovery is one component of assay validation, not a complete validation on its own. Other parameters, including precision, accuracy, linearity, limit of detection, limit of quantitation, and specificity, must also be evaluated. A well-validated assay demonstrates acceptable performance across all relevant parameters, beyond spike recovery.

The validation of the LuminEV assay for extracellular vesicle surface proteins included establishing linearity, spike-in recovery, inter- and intra-assay precision, and reproducibility between operators. The BD-tau assay evaluation included robustness, precision, dilution linearity, spike recovery, specificity, and limits of detection. These examples demonstrate that spike recovery is one element of a comprehensive validation strategy, and the results must be interpreted in the context of the other validation parameters.

Applications in Protein Assay Validation

Protein Quantification

Spike recovery is a standard component of protein quantification assay validation. Whether using ELISA, bead-based multiplex assays, or automated immunoassay platforms, demonstrating acceptable recovery in the intended sample matrix supports the reliability of quantitative results. The development of an automated IL-6 immunoassay included spike recovery testing in serum and plasma, with recovery values of 90 to 110 percent, as part of the validation that established the assay's reliability for clinical use.

The IL-6 assay development process illustrates the iterative nature of assay validation. Twenty-one antibodies in 441 antibody pairs were screened, and the antibody pair that most effectively captured and detected IL-6 was selected for the prototype assay. The selected pair was then evaluated for specificity, spike recovery, and sensitivity. This workflow demonstrates that spike recovery testing occurs after the antibody pair has been selected and is used to confirm that the chosen reagents perform acceptably in the intended sample matrix.

Extracellular Vesicle Analysis

Immunoassays for extracellular vesicle surface proteins present unique validation challenges because the analyte is associated with membranous particles instead of being freely soluble. A multiplexed immunoassay for tetraspanins CD9, CD63, and CD81 on extracellular vesicles was validated by establishing linearity, spike-in recovery, inter- and intra-assay precision, and reproducibility between operators. The spike recovery experiments demonstrated that the assay could accurately detect the target proteins in biofluids and culture supernatants without requiring prior EV isolation.

The LuminEV assay also demonstrated the utility of multiplexed detection for characterizing vesicle populations. Measurements of CD9, CD63, and CD81 in conditioned media from 15 cell lines revealed strong variations between cell types, and the assay detected cell type-specific surface markers including CD235a on erythrocytes, GAP43 on neurons, and CD68 on macrophages. The spike recovery results supported the reliability of these measurements across different sample types.

Biomarker Assay Development

Spike recovery is an essential validation step for biomarker assays intended for clinical or translational research. The development of TDP-43 immunoassays for plasma biomarker studies included qualification for specificity, signal-to-noise ratio, detection range, variation, spike recovery, and dilution linearity. The spike recovery results contributed to the overall assessment of assay performance, though subsequent investigation revealed that variable platelet recovery in archived plasma samples affected TDP-43 measurements, highlighting the importance of understanding pre-analytical variables in biomarker studies.

The TDP-43 study also demonstrated the value of developing assays on multiple technical platforms. Novel TDP-43 immunoassays were developed on three different platforms and qualified for the same set of parameters. This multi-platform approach provides confidence that the analytical performance is not an artifact of a single detection system.

Commercial Assay Evaluation

Spike recovery is also used to evaluate commercial immunoassays before adoption in a laboratory. The evaluation of a commercial brain-derived tau assay included assessment of robustness, precision, dilution linearity, spike recovery, specificity, and limits of detection. The spike recovery of 86 to 96 percent supported the assay's analytical performance, and the evaluation also examined matrix effects by comparing plasma and serum samples.

The BD-tau evaluation also assessed clinical performance in a traumatic brain injury cohort. Plasma BD-tau was elevated in severe-acute TBI compared to chronic-mixed TBI and unaffected controls, and the assay demonstrated high area under the curve values for distinguishing these groups. This combination of analytical and clinical validation provides a model for evaluating commercial assays before routine use.

Professional Escalation Criteria

When to Seek Additional Expertise

Certain situations warrant consultation with a laboratory director, assay development specialist, or biostatistician. These include persistent recovery failures that do not respond to standard troubleshooting, recovery values that vary widely between individual samples, and situations where the assay will be used for clinical decision-making or regulatory submissions. Institutional resources such as the clinical laboratory, core facility, or biosafety office can provide additional guidance.

The decision to escalate should be documented, including the nature of the problem, the troubleshooting steps already attempted, and the rationale for seeking additional expertise. This documentation supports the assay validation file and provides a record of the decision-making process.

When to Reconsider the Assay Format

If spike recovery remains unacceptable after troubleshooting, the assay format itself may need to be reconsidered. Options include changing the antibody pair, switching from a sandwich format to a competitive format, using a different detection system, or implementing a sample preparation step such as extraction or precipitation. These changes require re-validation of the assay, including repeat spike recovery experiments.

The IL-6 assay development process illustrates the importance of antibody pair selection. Twenty-one antibodies in 441 pairs were screened before the optimal pair was identified. If the initial antibody pair had produced unacceptable spike recovery, the screening process would have identified alternative pairs to test. This iterative approach to reagent selection is a standard part of assay development.

When to Document and Report

Spike recovery results should be documented in the assay validation file and reported in publications and regulatory submissions. The documentation should include the experimental design, the acceptance criteria, the results for each spike level and sample type, and any troubleshooting steps taken. Transparent reporting of validation data supports reproducibility and allows other laboratories to assess the assay's suitability for their applications.

The MIQE guidelines provide a framework for transparent reporting of assay validation data. While developed for qPCR, the principles of complete documentation and clear reporting apply to immunoassay validation as well. Following these principles ensures that spike recovery results are interpretable by other laboratories and that the assay's performance characteristics are fully disclosed.

Frequently Asked Questions

What is spike recovery in an immunoassay?

Spike recovery is a validation experiment where a known amount of purified analyte is added to a biological sample, and the assay's ability to detect that added analyte is measured. The percent recovery compares the measured increase in signal to the expected increase based on the amount added.

Why is spike recovery important for immunoassay validation?

Spike recovery detects matrix effects, which are interferences from sample components that can suppress or enhance the assay signal. These interferences can produce inaccurate measurements, and spike recovery provides a direct test of whether the assay performs reliably in the intended sample type.

How many spike levels should I use?

At least three spike levels spanning the low, middle, and high regions of the assay's dynamic range are recommended. Multiple levels detect concentration-dependent matrix effects that a single level would miss.

What is an acceptable spike recovery range?

A common acceptance range for research assays is 80 to 120 percent, but the appropriate range depends on the assay's intended use. Clinical assays may require tighter criteria, while exploratory research assays may tolerate wider ranges. The acceptance criteria should be established before running the experiment.

What does low spike recovery indicate?

Low spike recovery indicates that the sample matrix is suppressing the assay signal or degrading the added analyte. Possible causes include proteases, endogenous antibodies, or matrix components that inhibit the detection system.

What does high spike recovery indicate?

High spike recovery indicates that the sample matrix is enhancing the signal or contributing nonspecific reactivity. Possible causes include heterophilic antibodies, cross-reactivity with matrix components, or insufficient washing.

Can spike recovery detect all matrix effects?

No. Spike recovery measures the assay's ability to detect an added analyte, but it does not directly measure the accuracy of endogenous analyte measurements. Matrix components that affect the endogenous analyte differently than the added spike would not be detected.

How does spike recovery relate to other validation parameters?

Spike recovery is one component of assay validation, along with precision, accuracy, linearity, limit of detection, limit of quantitation, and specificity. A complete validation demonstrates acceptable performance across all relevant parameters.

Related Molecular Biology Guides

• Co-Immunoprecipitation Assay: Principles and Protocol
• Gel Filtration Chromatography Matrix: Principles and Applications
• BCA Assay Kit: Mechanism, Protocol, and Troubleshooting Guide
• Lyme Western Blot: Principles, Interpretation, and Pitfalls
• Yeast Two-Hybrid Assay: Principles, Methods, and Pitfalls

References and Further Reading

• Molecular Biology and Laboratory Methods. National Library of Medicine.
• Biosafety in Microbiological and Biomedical Laboratories. CDC and NIH.
• NIH Guidelines for Recombinant or Synthetic Nucleic Acid Molecules. National Institutes of Health.
• Addgene Protocols. Addgene.
• MIQE Guidelines. Clinical Chemistry.
• NIST Laboratory Programs. National Institute of Standards and Technology.
• Interference in ELISA.. Methods in molecular biology (Clifton, N.J.), 2023.
• A novel multiplexed immunoassay for surface-exposed proteins in plasma extracellular vesicles.. Journal of extracellular vesicles, 2024.
• Location and function of TDP-43 in platelets, alterations in neurodegenerative diseases and arising considerations for current plasma biobank protocols.. Scientific reports, 2024.
• Plasma brain-derived tau: analytical and clinical validation of the first commercial immunoassay.. medRxiv : the preprint server for health sciences, 2025.
• Development of a new automated IL-6 immunoassay.. Journal of immunological methods, 2022.

This article is educational and does not replace validated laboratory procedures, institutional biosafety review, manufacturer instructions, or professional interpretation.